Doug Cole joined Flagship Pioneering in 2001. He focuses on life science.

At Flagship, Doug has co-founded Ensemble Therapeutics, Foghorn Therapeutics (NASDAQ: FHTX), Inzen Therapeutics, Moderna (NASDAQ: MRNA), Permeon Biologics, Sigilon Therapeutics, (NASDAQ: SGTX), and Syros Pharmaceuticals (NASDAQ: SYRS). He has led investments in Agios Pharmaceuticals (NASDAQ: AGIO), Alvine Pharmaceuticals, Avedro (NASDAQ: AVDR, acquired by Glaukos), CombinatoRx (NASDAQ: ZLCS), Concert Pharmaceuticals (NASDAQ: CNCE), Denali Therapeutics (NASDAQ: DNLI), Editas (NASDAQ: EDIT), Quanterix Corporation (NASDAQ: QTRX), Receptos (NASDAQ: RCPT, acquired by Celgene), Seventh Sense Biosystems, Tetraphase Pharmaceuticals (NASDAQ: TTPH), and Torque.

He currently serves on the board of directors of Denali Therapeutics, Cygnal Therapeutics, Foghorn Therapeutics, KSQ Therapeutics, Inzen Therapeutics, Repertoire Immune Medicines, Sana Biotechnology (NASDAQ: SANA), and Sigilon Therapeutics. He formerly served on the board of directors of Avedro, AVEO Oncology (NASDAQ: AVEO), CombinatoRx, Concert Pharmaceuticals, CGI, Moderna, Morphotek (acquired by Eisai Pharmaceuticals), Receptos, Resolvyx, Selecta (NASDAQ: SELB), Seventh Sense, Taris (acquired by JNJ), and Tetraphase.

Before joining Flagship, Doug was instructor in neurology at Harvard Medical School and assistant in neurology at the Massachusetts General Hospital; medical director at Cytotherapeutics, in Providence, Rhode Island; and program executive at Vertex Pharmaceuticals, Inc., in Cambridge, Mass.

He holds an A.B. magna cum laude with high distinction in English from Dartmouth College, where he was a senior fellow and a member of Phi Beta Kappa, and an M.D. from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, and in neurology at the Massachusetts General Hospital in Boston, Mass.

Doug is a member of the scientific advisory board and the board of directors of the Spinal Muscular Atrophy Foundation.

Alan Crane is a Partner and Entrepreneur at Polaris Partners focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (NASDAQ:CERU), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals and Arsia Therapeutics. In addition, he currently serves on the board of Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (acquired by Bristol Myers Squibb).

From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade™ which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.

Alan earned a BA in Biology, summa cum laude, from Harvard College, an MA in Cellular and Developmental Biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.

Mahesh is the President and CEO of Omega Therapeutics (Nasdaq: OMGA), a clinical-stage biotechnology company pioneering a new field of epigenomic programming to use mRNA therapeutics as programmable epigenetic medicines. At Omega, he has led the translation of completely new science into a drug development and therapeutic platform with a broad pipeline in oncology, regenerative medicine, immunology, inflammatory conditions, and important monogenic conditions. As Omega’s CEO, Mahesh has raised $350 million through private rounds (series A, B, C) and a successful IPO in July 2021. Prior to Omega, he held the position of CEO of Macrolide Pharma. Upon his arrival, Mahesh immediately assessed the science of the company, leadership, core competencies, and pipeline to optimize a path forward for the highest shareholder return.

Before his CEO positions, Mahesh held numerous leadership roles at Novartis Pharmaceuticals most recently as a corporate-level Vice President and US franchise head leading the Oncology solid tumors business, President of Africa, President of Egypt and Regional Vice President of strategy and business development for 95+ emerging markets from Africa to Australia, where he oversaw execution of over 50 partnership deals.  He has led over 10 product launches in the U.S. and across global markets.  He has had the distinction of successfully leading his teams in Egypt though the military coup of 2013 and Africa through the Ebola crisis of 2014 and the oil-currency crisis of 2015.  He over-delivered on business results despite these existential crises.

Prior to entering the pharmaceutical industry, Mahesh worked for the global management consulting firm, McKinsey and Company where he led and worked on projects across pharmaceuticals, medical devices, telecom, technology and private equity.

Mahesh has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology, where he completed his M.S. in engineering, and the University of Bombay, where he completed undergraduate studies in engineering.

John Lepore, M.D. is CEO-Partner at Flagship Pioneering and CEO of ProFound Therapeutics, an early stage biotechnology company harnessing the expanded human proteome to identify novel, first-in-class protein drugs and drug targets.

Dr. Lepore joined ProFound after 17 years at GSK where he had extensive experience leading international R&D organizations across diverse therapeutic areas. He was most recently Senior Vice President, Head of Research at GSK where he led a large organization of scientists and physicians focused on leveraging the science of immunology, human genetics and genomics, and applying advanced technologies to identify novel drug targets, discover new therapeutic molecules, and demonstrate proof of mechanism in clinical studies.

Dr. Lepore joined GSK in 2006 and held roles of increasing responsibility including VP of Clinical Pharmacology and Discovery Medicine, VP and Head of the Heart Failure Discovery Performance Unit, SVP and Head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit, and SVP R&D Pipeline responsible for end-to-end R&D activities across multiple therapeutic areas. He was also Interim Head of Business Development and played a key role in multiple preclinical and clinical deals to augment the GSK pipeline. At GSK, he chaired the Research Review and Investment Boards, responsible for project prioritization and capital allocation across research and early clinical development.

Before joining GSK, Dr. Lepore was on the faculty of the Cardiovascular Medicine Division of the Department of Medicine at the University of Pennsylvania, where his lab investigated the transcriptional regulation of cardiovascular development, and he was attending physician on the academic cardiology service.

Dr. Lepore received his B.S. in Biology from the University of Scranton and his medical degree from Harvard Medical School where he was a Howard Hughes Medical Institute Research Scholar. He subsequently trained in internal medicine and cardiology and served as Medical Chief Resident at Massachusetts General Hospital, with post-doctoral training at the Harvard School of Public Health.

Dr. Lepore was previously on the Board of Directors of ViiV Healthcare, the Altius Institute, and the Biotechnology Innovation Organization (BIO), and the Scientific Advisory Boards of Medicxi Ventures and Hatteras Ventures. He presently serves on the Board of Directors of ProFound Therapeutics, KSQ Therapeutics, and the Innovation Growth Board of Mass General Brigham.

Ravi Mehrotra joined Flagship Pioneering in 2023. He works with  Flagship Growth companies to help maximize value creation opportunities for their bioplatforms.

Prior to joining Flagship, Ravi spent 20+ years in biotechnology equity research and investment banking and he has held various executive team operational roles. He was previously Senior Managing Director on Evercore ISI’s Biotech team and served in senior equity research roles at Credit Suisse and Cowen. Ravi started his career on Wall Street in 1997 at Bankers Trust-Alex Brown/Deutsche Bank.

Ravi developed a “macro-micro” approach to equity research encompassing thought leadership and industry analysis on a broad range of topics including bioparma R&D productivity, biotech business models, the gene and cell therapy revolution, and drug pricing. He was the number one ranked biotechnology analyst in both Institutional Investor and Extel surveys for multiple years and has been involved in over 200 IPO’s and financings globally.

Ravi holds a B.S. (Honors) and a Ph.D. in Biochemistry and Molecular Biology from The Wellcome Trust Center, Manchester University, UK.

Richard Moscicki has more than 25 years of leadership experience in translational medicine, clinical development, regulatory affairs and medical affairs in the pharmaceutical industry.

Rich is currently the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). From 2013 to 2017, prior to joining PhRMA, he served as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER). Rich was senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013. He was Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance, as well as all aspects of clinical research and medical affairs.

Rich is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. He completed his residency in internal medicine, followed by a fellowship at Massachusetts General Hospital in clinical immunology and immunopathology. He remained on staff at MGH and on the faculty of Harvard Medical School from 1979 until 2013. Rich received his medical degree from Northwestern University Medical School.

Frank Stegmeier is an industry-leading expert in genetics, cancer biology and functional genomics who has led the industrialized application of functional genomics for oncology drug discovery in the pharmaceutical industry. Prior to joining KSQ Therapeutics, Frank served as Director and Head of Global Oncology Target Discovery at the Novartis Institutes for Biomedical Research (NIBR), where he was responsible for developing the early oncology drug discovery portfolio. Frank also led the therapeutic siRNA research strategy at Novartis and directed the Cancer Cell Line Encyclopedia collaboration with the Broad institute. During his tenure at Novartis, Frank and his team identified more than a dozen novel oncology targets and advanced multiple chemical entities addressing these targets into preclinical development. He also led the biology efforts to advance the PKC inhibitor Sotrastaurin into phase I clinical trials in lymphomas and uveal melanoma. Frank was awarded the prestigious Novartis VIVA Leading Scientist Award for his vision, scientific excellence and innovative leadership.

Frank earned his PhD in biology from MIT and was a Helen Hay Whitney postdoctoral fellow at Harvard Medical School in Dr. Stephen Elledge’s lab. He has authored numerous patents and published in top-tier scientific journals including Cell, Nature, Science, and Nature Medicine.

Qasim Rizvi is a trained surgeon and highly accomplished health care executive with broad experience in the biopharmaceuticals industry. He has a distinguished track record of innovation and operational excellence, coupled with a strong commitment to collaboration and teambuilding. Prior to joining KSQ, Dr. Rizvi was senior vice president of operations & chief commercial officer at Kiniksa Pharmaceuticals. He held previous positions at Genentech, where he most recently served as vice president and franchise head of Tecentriq®, with commercial responsibilities for Genentech’s cancer immunotherapy portfolio. Earlier, he led Roche’s hematology franchise, as VP of global product strategy and lifecycle leader for Hemlibra^® for hemophilia A. Dr. Rizvi has a record of success in building exceptional teams that deliver results. He has extensive launch experience in the oncology space; having launched Herceptin^®, Perjeta^® and Kadcyla^® for HER2-positive breast cancer as well as Venclexta^® for chronic lymphocytic leukemia and Gazyva^® for follicular lymphoma. Under his leadership, Rituxan Hycela^® received FDA approval as the first sub-cutaneous treatment for non-Hodgkin’s lymphoma. Prior to joining Genentech, Dr. Rizvi was at Novo Nordisk and Eli Lilly, where he served in numerous roles in sales, marketing, business development and new product planning. Dr. Rizvi earned an MB.ChB. from the University of Dundee Medical School in Scotland. He completed his residency in general surgery, including rotations in neurosurgery, orthopedics, ENT and accident and emergency care. He also holds an M.B.A. from the Ross School of Business at the University of Michigan.